Moleculin Biotech
@moleculinbio
Followers
4,751
Following
624
Media
407
Statuses
697
Moleculin (NASDAQ: $MBRX) is a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant cancers and viruses.
Houston, TX
Joined June 2016
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Madrid
• 988111 Tweets
برشلونة
• 863044 Tweets
Barca
• 552143 Tweets
Mbappe
• 455607 Tweets
#ElClásico
• 335153 Tweets
Bernabéu
• 312499 Tweets
Lamine Yamal
• 279002 Tweets
Vinicius
• 172997 Tweets
選挙の日
• 169001 Tweets
Lewandowski
• 160387 Tweets
Topuria
• 153017 Tweets
Hansi Flick
• 149122 Tweets
Michelle Obama
• 137693 Tweets
Ancelotti
• 128768 Tweets
Ilia
• 114494 Tweets
#كلاسيكو_الارض
• 60264 Tweets
#precure
• 46179 Tweets
Checo
• 46051 Tweets
Sainz
• 43389 Tweets
Cruzeiro
• 38979 Tweets
الريال
• 32884 Tweets
Mendy
• 32414 Tweets
#仮面ライダーガヴ
• 31828 Tweets
انشيلوتي
• 20764 Tweets
投票完了
• 18767 Tweets
Gerson
• 18569 Tweets
ليفا
• 16522 Tweets
Jokic
• 11043 Tweets
#ブンブンジャー
• 10855 Tweets
$MBRX Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of
#SarcomaLungMetastases
.
3
17
63
Today we would like to recognize survivors, to
#celebratelife
and inspire those fighting. $MBRX
@SurvivorsDay
#NCSD2021
#Oncology
1
4
36
We have a team of industry experts with a proven track record. Learn more about our team at .
#ManagementTeam
#Leaders
#TrackRecord
$MBRX
1
4
26
Soft tissue
#sarcoma
represents an area of significant unmet need.
$MBRX
#CureSarcoma
#SarcomaAwareness
1
9
18
We are committed to solving some of the toughest challenges in highly resistant cancers and viruses.
$MBRX
#Oncology
#AcuteMyeloidLeukemia
#SoftTissueSarcoma
4
3
25
We are excited to continue building upon our progress and advancing our Annamycin clinical development programs.
$MBRX
#Oncology
1
4
26
In recognition of
#WorldBrainTumorDay
, we encourage you to help raise awareness around the world! Check out to get involved.
$MBRX
#EndBrainTumors
1
7
18
Jon Foster, CFO of Moleculin provides insight into our ongoing development programs for
#STSLungMets
. Watch the full video here:
$MBRX
#Oncology
#AcuteMyeloidLeukemia
#SoftTissueSarcoma
0
0
19
February is
#NationalCancerPreventionMonth
. Get more information about cancer prevention to keep you and your loved ones healthy:
$MBRX
@AACR
#Oncology
#AcuteMyeloidLeukemia
#STSLungMets
0
6
20
Moleculin Announces 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model
1
2
10
The FDA has granted Orphan Drug Designation to Annamycin for treatment of soft tissue sarcomas. This is now the second Orphan Drug designation for Annamycin.
0
2
8
Today we announced positive interim results in a pediatric brain tumor Phase 1 clinical trial at Emory University. View press release for more details.
1
1
12
We are pleased to have received clearance to initiate our Phase 1b/2 clinical trial of Annamycin in the first of several planned U.S. clinical sites for the treatment of
#SarcomaLungMetastases
.
$MBRX
#LungMets
#Sarcoma
1
1
9
$MBRX
#2021ScorecardSeries
: March 30, 2021: Received FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases.
#oncology
#acutemyeloidleukemia
#softtissuesarcoma
#lungmetastases
1
2
10
A second round of independent laboratory testing has confirmed the antiviral activity of WP1122 against coronavirus.
5
5
10
$MBRX
#2021ScorecardSeries
: February 02, 2021: Announced 100% Survival Achieved in Osteosarcoma Lung Metastases Animal Model.
#oncology
#acutemyeloidleukemia
#softtissuesarcoma
#lungmetastases
1
2
9
Independent research shows active compound in WP1122 reduces coronavirus replication in vitro by 100%.
3
7
7
We have entered into an agreement with Sterling Pharma USA LLC for US production of WP1122 to support expanded development efforts in preparation for submitting a request to the FDA for IND status for WP1122 for the potential treatment of COVID-19.
2
1
9
Today we announced news that new antiviral drug candidates demonstrate in vitro activity against HIV. View press release for more details.
1
1
8
$MBRX Awarded New Rare Pediatric Disease Designation from U.S. FDA for
#WP1066
for the Treatment of
#Ependymoma
.
#RPDD
#RareDiseasae
#OrphanDrug
#BrainTumors
#SpinalCordTumor
#RarePediatricDiseaseDesignation
0
1
7
We are committed to solving some of the toughest challenges in highly resistant cancers and viruses.
#STSLungMets
#Sarcoma
#AcuteMyeloidLeukemia
#Oncology
1
2
7
In recognition of
#GlioblastomaAwarenessDay
, we would like to shine a light on this complex, treatment-resistant, and deadly type of brain cancer. Learn more about
#GBM
at .
$MBRX
#Glioblastoma
0
3
7
We successfully completed a pre-IND meeting with the FDA regarding the development plan for Annamycin and intend to file an IND using Annamycin for the treatment of soft tissue sarcomas with lung metastases by year-end.
1
0
7
Moleculin receives FDA permission to begin a clinical study of Annamycin for the treatment of soft tissue sarcoma lung metastases.
0
2
6
Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases.
$MBRX
#oncology
1
2
7
$MBRX Moleculin Announces FDA Approval of Annamycin IND
0
1
6
#MarkYourCalendars
: We are presenting at the upcoming H.C. Wainwright BioConnect Conference.
$MBRX
@HCWCO
#HCWCO
4
1
6
$MBRX Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of
#SarcomaLungMetastases
.
#Sarcoma
#LungMets
0
1
5
Moleculin to present animal data demonstrating highly improved activity of Annamycin against acute myeloid leukemia in combination with Ara-C at the 62nd Annual Meeting & Exposition of the American Society for Hematology.
1
1
5
Walter Klemp, President and CEO of Moleculin, speaks to the Company's rebranding and continued commitment to solving some of the toughest challenges in highly resistant cancers and viruses.
$MBRX
#STSLungMets
#Sarcoma
#AcuteMyeloidLeukemia
#Oncology
1
2
6
Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme.
$MBRX
#Glioblastoma
#GBM
#oncology
#GlioblastomaMultiforme
2
2
6
Walter Klemp, CEO of $MBRX, gives a brief overview of the full annamycin opportunity.
#SoftTissueLungMets
#STSLungMets
#Sarcoma
#Oncology
#AcuteMyeloidLeukemia
3
1
6
Want to stay in the loop with our latest news, events and filings? Sign up for email alerts here:
$MBRX
0
1
5
We are advancing a growing pipeline of clinical programs for highly resistant cancers and viruses.
$MBRX
#STSLungMets
#Sarcoma
#AcuteMyeloidLeukemia
#Oncology
1
2
6
Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases.
$MBRX
#SoftTissueLungMets
#STSLungMets
#Sarcoma
#Oncology
1
3
5
We are joining LUNG FORCE this November during
#LungCancerAwarenessMonth
to raise awareness of the leading cancer killer, lung cancer. Learn more at .
@LungAssociation
@LUNGFORCE
#LCAM
#LungCancer
#SoftTissueSarcoma
#LungMetastases
$MBRX
15
1
6
We have received notification from Nasdaq that trading in Moleculin's common stock will resume on Thursday, May 28, 2020.
3
2
6
What a great day for our company and what a great photo this is! $MBRX
#cancer
#cancerawareness
#AML
0
0
5
Additional independent research further supports glucose metabolism as important COVID-19 target.
1
1
5
Members of our management will present at the virtual H.C. Wainwright BioConnect 2021 Conference on Monday, January 11th at 6AM ET.
0
0
4
The FDA has granted our request for a Pre-IND Meeting to provide guidance regarding our plans to study drug candidate WP1122 in a clinical trial for patients with COVID-19. Additional information can be found in today’s press release.
0
3
4
We just signed an agreement with MD Anderson for our Leukemia drug. Read more here: $MBRX
#beatcancer
#Leukemia
0
1
4
Today we announced preclinical data confirming the efficacy of Annamycin in lung metastases.
1
1
5
We have entered into an agreement with the University of Campinas in São Paulo, Brazil to further enable collaboration into our research on the anti-viral capabilities of our drug candidate WP1122, specifically for the coronavirus.
0
0
5
$MBRX
#2021ScorecardSeries
: February 01, 2021: Signed Agreement with Catalyst Clinical Research to Begin Sarcoma Trial.
#oncology
#acutemyeloidleukemia
#softtissuesarcoma
#lungmetastases
3
2
5
The FDA approves 3 "Rare Pediatric Disease" designations for our drug candidate WP1066. Please read our press release for more details.
1
3
4
Moleculin Biotech $MBRX gets good verbal OK from FDA which should cut time to phase 1/2 trial down via
@TheStreet
0
2
4
We are very pleased to announce our recently refreshed website! Check it out here:
$MBRX
#STSLungMets
#Sarcoma
#AcuteMyeloidLeukemia
#Oncology
0
3
5
#NowAvailable
: Our presentation at the H.C. Wainwright 23rd Annual Global Investment Conference. Access the webcast here:
$MBRX
#oncology
#viruses
#sarcoma
#acutemyeloidleukemia
#COVID
#Glioblastoma
1
2
5
Walter Klemp, CEO of $MBRX, speaks to the potential of its lead development program.
#SoftTissueLungMets
#STSLungMets
#Sarcoma
#Oncology
#AcuteMyeloidLeukemia
7
1
5
Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update.
$MBRX
#oncology
#sarcoma
#acutemyeloidleukemia
#glioblastoma
#lungsarcoma
4
1
4
We are pleased to announce positive interim results in our adult glioblastoma clinical trial. Please read our press release for more details.
1
0
4
Want to stay in the loop with our latest news, events and filings? Sign up for email alerts here:
$MBRX
0
2
4
Moleculin to Present at the H.C. Wainwright Global Investment Conference.
$MBRX
@HCWCO
#HCWCO
#STSLungMets
#Sarcoma
#AcuteMyeloidLeukemia
#Oncology
#COVID
#COVID19
0
1
3
We have entered into an agreement with ImQuest Biosciences to expand in vitro and in vivo testing of WP1122, our lead drug candidate for the treatment of COVID-19.
0
2
4
About every two and a half minutes, someone in the U.S. is diagnosed with lung cancer. Join
@LUNGFORCE
during
#LungCancerAwarenessMonth
to help raise awareness!
@LungAssociation
#LCAM
#LungCancer
#SoftTissueSarcoma
$MBRX
13
1
4
Results of a repeated round of in vitro testing received on June 1, 2020, confirm that WP1122 has an antiviral effect on Human Coronavirus 229E ("HCoV-229E"), a surrogate of SARS-CoV-2, the virus responsible for COVID-19.
2
1
4
We are pleased to announce that our proof of concept clinical trial to evaluate our p-STAT3 inhibitor, WP1220, for the topical treatment of Cutaneous T-Cell Lymphoma (CTCL) has reached full enrollment.
0
1
4
The full opportunity of Annamycin proves potential for significant upside. Watch the full video at:
$MBRX
@InvestorVirtual
#VirtualInvestor
#STSLungMets
#Sarcoma
#AcuteMyeloidLeukemia
#Oncology
1
2
4
1
1
2
Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors.
$MBRX
#oncology
#sarcoma
#lungmets
#acutemyeloidleukemia
0
1
4
Our Chairman and Chief Executive Officer, Wally Klemp, will participate on the COVID-19 panel at Maxim Group's Infectious Disease Virtual Conference on May 5, 2020.
4
0
4
2
2
3
Want to stay in the loop with our latest news, events and filings? Sign up for email alerts here:
$MBRX
#SoftTissueLungMets
#STSLungMets
#Sarcoma
#Oncology
#AcuteMyeloidLeukemia
3
2
4
Today we entered into an agreement with UTMB to conduct research on our patented portfolio of molecular inhibitors, including drug candidate, WP1122, for antiviral properties against a range of viruses, including Coronavirus.
0
1
4
Today at 4:30PM ET our Chairman & CEO, Wally Klemp, will host a web-based conference call to discuss the recent discovery that the active compound in WP1122 reduces in vitro replication of SARS-CoV-2 by 100%. Click below for more details.
1
1
4
Emory University Clinical Trial Review Committee to move forward with an Investigator Initiated clinical trial of our immune-stimulating/transcriptional-modulator, WP1066, for the treatment of pediatric brain tumors. $MBRX
0
1
4
Today we announced that recruiting has begun and the first patient has been enrolled in the Emory University Phase 1 clinical trial of WP1066 for the treatment of brain tumors in children.
0
1
4
Our CEO, Walter Klem highlights the interim data we recently announced in our Phase 1b/2 clinical trial in soft tissue sarcoma lung metastases.
$MBRX
#Oncology
#SoftTissueSarcoma
#LungMetastases
#LungCancer
4
2
4
$MBRX
#2021ScorecardSeries
: Over the next month, we will highlight our many accomplishments made throughout 2021.
#oncology
#acutemyeloidleukemia
#softtissuesarcoma
#lungmetastases
2
2
4
Today we announced the filing of new patents covering the production and reconstitution of Annamycin, which is currently in two clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML). $mbrx
0
1
4
Today we announced the expansion of Annamycin production commitments in response to positive AML clinical trial activity and the potential expansion of indications for use to include lung-localized tumors. $MBRX
1
2
3
Walter Klemp, President and CEO of $MBRX, provides an overview of the Company’s development programs. Watch the full video at:
$MBRX
@InvestorVirtual
#VirtualInvestor
#STSLungMets
#Sarcoma
#AcuteMyeloidLeukemia
#Oncology
0
2
3
As
#BrainTumorAwarenessMonth
comes to a close, we encourage you take action and raise awareness to make lasting change for the brain tumor community. Learn more at:
@NBTStweets
$MBRX
#BrainTumorAwarenessMonth
#Glioblastoma
#GBM
0
1
3
We remain encouraged by data we continue to generate with our lead asset and look forward to unlocking its full potential in
#AcuteMyeloidLeukemia
and
#SoftTissueSarcoma
.
$MBRX
#AML
#STS
#Oncology
0
0
3
A young
#leukemia
survivor took medical
#marijuana
rather than undergoing
#chemo
. What do you think?
@Newsweek
0
2
3
#InCaseYouMissedIt
! Walter Klemp, CEO of Moleculin, recently presented at the H.C. Wainwright 23rd Annual Global Investment Conference. Access the webcast replay here:
$MBRX
#oncology
#viruses
#sarcoma
#acutemyeloidleukemia
#COVID
#Glioblastoma
1
2
3
Our Senior Chief Medical Officer, Dr. Paul Waymack highlights, the interim data we recently announced from our Phase 1b/2 clinical trial of annamycin.
$MBRX
#oncology
#acutemyeloidleukemia
#softtissuesarcoma
#lungmetastases
4
1
3
Dr. John Paul Waymack, Senior Chief Medical Officer of $MBRX, provides an overview of the Company’s ongoing clinical development programs.
#SoftTissueLungMets
#STSLungMets
#Sarcoma
#Oncology
#AcuteMyeloidLeukemia
7
1
3
Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma.
$MBRX
#AcuteMyeloidLeukemia
#AML
#SoftTissueSarcoma
#LungMets
#oncology
1
1
3
In recognition of
#NationalHealthCenterWeek
, we would like to shine a light on all heath centers who are committed to improving overall health and wellness. Learn more at:
#ThankYou
#valueCHCs
0
2
3
#NowAvailable
! Our presentation at the H.C. Wainwright BioConnect Conference is now available! Access the webcast here:
$MBRX
@HCWCO
#HCWCO
8
1
3
Today we announced financial results for the second quarter and provided potential upcoming milestones and recent corporate developments. $MBRX
0
1
3
Our presentation at the H.C. Wainwright Global Investment Conference is now available for viewing! Access the webcast here:
$MBRX
@HCWCO
#HCWCO
#STSLungMets
#Sarcoma
#AcuteMyeloidLeukemia
#Oncology
0
2
3
We're extremely excited to announce positive guidance from the FDA! Read the news: $MBRX
#leukemia
#childhoodcancer
0
1
3